Paris-based Rivercell raises $25M seed led by HV to build its AI Virtual Cell model that predicts how human cells respond to drugs. Explore how it works.

The TAURUS-1980 Phase I study has dosed its first participants, testing AV-1980R as a preventive tau vaccine. Read what researchers will assess next.

Tempus expands its collaboration with Moderna and Merck to support potential commercialization of a personalized cancer ...

FDA approves Rhapsido (remibrutinib) for adults with symptomatic dermographism beyond CSU. Get the full details on this newly ...

Ultragenyx agreed to sell a rare pediatric disease priority review voucher for $210 million after GENGLYCOS approval. Explore ...

A Dutch court barred Merck from making or selling Keytruda SC in eight European markets, ruling in Halozyme’s patent dispute. Read what the order means now.

Florida-based Processa Pharmaceuticals (Nasdaq: PCSA) has acquired Vidya Therapeutics, a private clinical-stage company developing VT-7208, a CNS-penetrant covalent Bruton's tyrosine kinase inhibitor ...

Biohub, DOE, NIH, Google DeepMind, Meta and research partners pledge $1.8B for an open-source AI virtual cell. Read more: Explore the initiative's goals.

SurVaxM missed its overall survival endpoint in glioblastoma, but patients 65 and younger saw a significant benefit. Read the trial results and context.

AmyriAD Therapeutics acquires Recognify Life Sciences in an all-share deal to gain RL-007 (inidascamine), a pro-cognitive candidate. Read full details.

EPI-321 data show increased lean muscle volume and strength after six months in six people with FSHD. Read the full Phase I/II study results and updates.

Biohaven grants Ono Pharma exclusive rights to its MoDE pan-IgG degrader portfolio in Japan and Asia, with $80M upfront. Read the full deal details now.